Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study

[1]  F. Peyvandi,et al.  Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis , 2021, Intensive Care Medicine.

[2]  M. Netea,et al.  The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity , 2021, The Lancet Respiratory Medicine.

[3]  M. H. Bashari,et al.  The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis , 2021, Clinical Epidemiology and Global Health.

[4]  V. Cuervas-Mons,et al.  Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain , 2021, Medicine.

[5]  Dave L Dixon,et al.  Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 , 2021, Nature Reviews Immunology.

[6]  R. Chemaly,et al.  Immune reconstitution and severity of COVID‐19 among hematopoietic cell transplant recipients , 2021, Transplant infectious disease : an official journal of the Transplantation Society.

[7]  L. Notarangelo,et al.  BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review , 2021, Research square.

[8]  M. Bassetti,et al.  Duration of isolation and precautions in immunocompromised patients with COVID-19 , 2021, Journal of Hospital Infection.

[9]  B. Wörmann,et al.  2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy , 2021, European Journal of Cancer.

[10]  J. Ramos-Rincón,et al.  [Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry]. , 2020, Revista clinica espanola.

[11]  V. Jiménez‐Yuste,et al.  Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study , 2020, Journal of Hematology & Oncology.

[12]  C. Solano,et al.  Risk factors and outcome of COVID-19 in patients with hematological malignancies , 2020, Experimental Hematology & Oncology.

[13]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[14]  D. Kontoyiannis,et al.  Are all patients with cancer at heightened risk for severe Coronavirus Disease 2019 (COVID-19)? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Bagnarelli,et al.  Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[16]  L. Bashoura,et al.  Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  A. Meert,et al.  Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies , 2018, Leukemia & lymphoma.

[18]  J. Connors,et al.  Venous thromboembolism incidence in hematologic malignancies. , 2019, Blood reviews.

[19]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[20]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[21]  R. Chemaly,et al.  Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[24]  Kwan Hyung Kim,et al.  Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies , 2009, Critical care.

[25]  Guy E. Thwaites,et al.  The Diagnosis and Management of Tuberculous Meningitis , 2002, Practical Neurology.

[26]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.